Management of the Lack of Blood Return on a Central Venous Catheter (CVC) Before Chemotherapy (NCT05100355) | Clinical Trial Compass
CompletedNot Applicable
Management of the Lack of Blood Return on a Central Venous Catheter (CVC) Before Chemotherapy
France92 participantsStarted 2022-03-09
Plain-language summary
Compare two methods of managing the lack of CVC blood return : opacification using contrast media injection or radio-clinical method with a simple chest X-ray followed by a rapid infusion of physiological serum
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female or male, Age ≥ 18 years at time of study entry.
* Undergoing systemic chemotherapy on a CVC. Immunotherapy and targeted therapies are among the systemic therapies that are authorised
* Having already received at least one administration of treatment without difficulty.
* Coming for a new administration of treatment authorised by the usual biological assessment.
* First episode of lack of CVC blood return despite the usual positioning and injection- aspiration manoeuvres
* No abnormality on inspection or palpation (turning) of the CVC.
* Patient has valid health insurance.
* Patient information and signature of informed consent.
Exclusion Criteria:
* Previous episode of lack of CVC blood return whether explored or not.
* Patient currently treated in an interventional therapeutic trial.
* Patient with a Picc-line implantable device.
* Suspected CVC infection or thrombosis.
* Planned chemotherapy with vesicant agent (anthracyclines).
* Possible CVC disjunction.
* Allergy to X-ray contrast agent or creatinine clearance below 30ml/min prohibiting an iodine injection.
* Pregnant, likely to be pregnant or breastfeeding woman.
* Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian.
* Impossibility of undergoing medical monitoring of the trial for geographical, social or psychological reasons, social or psychological reasons.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Compare the delay between randomisation (determination of the lack of blood return) and the decision to initiate or not the chemotherapy protocol on the same day, for both procedures